propranolol
Trade name: inderal
Approved
Nov 13, 1967
Propranolol is a nonselective, beta-adrenergic receptor-blocking agent possessing no other autonomic nervous system activity. At dosages greater than required for beta blockade, propranolol also exerts a quinidine-like or anesthetic-like membrane action, which affects the cardiac action potential. Among the factors that may be involved in contributing to the antihypertensive action include: (1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of tonic sympathetic nerve outflow from vasomotor centers in the brain. Although total peripheral resistance may increase initially, it readjusts to or below the pretreatment level with chronic use of propranolol. Effects of propranolol on plasma volume appear to be minor and somewhat variable. In angina pectoris, propranolol generally reduces the oxygen requirement of the heart at any given level of effort by blocking the catecholamine-induced increases in the heart rate, systolic blood pressure, and the velocity and extent of myocardial contraction. Propranolol may increase oxygen requirements by increasing left ventricular fiber length, end diastolic pressure, and systolic ejection period. The net physiologic effect of beta-adrenergic blockade is usually advantageous and is manifested during exercise by delayed onset of pain and increased work capacity. Propranolol exerts its antiarrhythmic effects in concentrations associated with beta-adrenergic blockade, and this appears to be its principal antiarrhythmic mechanism of action. In dosages greater than required for beta blockade, propranolol also exerts a quinidine-like or anesthetic-like membrane action, which affects the cardiac action potential. The significance of the membrane action in the treatment of arrhythmias is uncertain. The mechanism of the anti-migraine effect of propranolol has not been established. Propranolol is indicated in the management of hypertension. It may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Also is indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris; for the prophylaxis of common migraine headache. In addition, is used to improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Due to the high penetration across the blood–brain barrier, propranolol causes sleep disturbances such as insomnia and vivid dreams, and nightmares. Dreaming (rapid eye movement sleep, REM) was reduced and increased awakening. — NCATS
Clinical trial activity
321 trials · 270 clinical orgs · 56 marketing orgs
Earliest trial started Sep 1, 1977 (NCT00000493)
Timeline
1960s
1970s
- Sep 4, 1973
Akrimax Pharmaceuticals — NDA Secondary Org
- Jan 1, 1977
Earliest Phase 3 Sponsor(trial)
- Jun 15, 1979
American Home Products — Marketing Organization
1980s
- Apr 19, 1983
Ani Pharmaceuticals — NDA Secondary Org
- Apr 19, 1983
Ani Pharmaceuticals — Marketing Organization
- Jul 3, 1985
American Home Products — NDA Secondary Org
- Jul 30, 1985
DAVA Pharmaceuticals — Marketing Organization
- Aug 6, 1985
Schering — Marketing Organization
- Aug 6, 1985
Schering-Plough — Marketing Organization
- Sep 9, 1985
Duramed Research — Marketing Organization
- Oct 22, 1985
ANDA Repository — Marketing Organization
- Oct 22, 1985
Innogenix — Marketing Organization
- Nov 19, 1985
Mylan — Marketing Organization
- Apr 11, 1986
Teva — Marketing Organization
- Apr 14, 1986
Vintage — Marketing Organization
- Apr 14, 1986
Endo Pharmaceuticals — Marketing Organization
- Apr 14, 1986
PH HEALTH — Marketing Organization
- Apr 18, 1986
Watson Pharmaceuticals — Marketing Organization
- May 15, 1986
Actavis — Marketing Organization
- Jul 7, 1986
Boehringer Ingelheim — Marketing Organization
- Aug 4, 1986
Amici — Marketing Organization
- Oct 22, 1986
Par Pharmaceuticals — Marketing Organization
- Oct 22, 1986
Strides Pharma Science — Marketing Organization
- Oct 22, 1986
AiPing Pharm Inc — Marketing Organization
- Jan 1, 1987
Earliest Phase 2 Sponsor(trial)
- Apr 1, 1987
Rising Pharmaceuticals — Marketing Organization
- May 5, 1987
Interpharm — Marketing Organization
- May 15, 1987
Roxane Laboratories — Marketing Organization
- May 15, 1987
West-Ward Pharmaceutical — Marketing Organization
- Jan 26, 1988
Warner Chilcott — Marketing Organization
- Apr 6, 1988
Impax Laboratories — Marketing Organization
- Jun 8, 1988
Superpharm — Marketing Organization
- Apr 11, 1989
Inwood Laboratories — Marketing Organization
1990s
- Jan 1, 1996
Earliest Phase 1 Sponsor(trial)
2000s
- Aug 29, 2000
Athenex, Inc. — Marketing Organization
- Aug 29, 2000
Chartwell Pharmaceuticals — Marketing Organization
- Aug 31, 2001
Fresenius — Marketing Organization
- Feb 26, 2003
Fosun — Marketing Organization
- Feb 26, 2003
Allied Pharmaceutical Services — Marketing Organization
- Jan 26, 2007
Nortec Dev Assoc — Marketing Organization
- Feb 15, 2007
EXTROVIS — Marketing Organization
- Jan 10, 2008
Northstar Healthcare — Marketing Organization
- Jan 31, 2008
Hikma — Marketing Organization
- Jun 2, 2008
IPCA Laboratories Ltd. — Marketing Organization
- Mar 6, 2009
Upsher-Smith Laboratories — Marketing Organization
2010s
- Mar 25, 2011
Zydus Discovery DMCC — Marketing Organization
- Jul 15, 2011
R.P. Scherer — Marketing Organization
- Jul 15, 2011
Adare Pharmaceuticals — Marketing Organization
- Mar 14, 2014
Pierre Fabre — NDA Secondary Org
- Mar 14, 2014
Pierre Fabre — Marketing Organization
- Mar 14, 2014
Eton Pharmaceuticals, Inc. — Marketing Organization
2020s
- Jan 6, 2020
Amta — Marketing Organization
- Jan 12, 2024
Lupin — Marketing Organization
- Jan 27, 2026
Mankind Pharma — Marketing Organization
Indications
Approved for
Studied for
- Accidents · Phase 3
- Acute Kidney Injury · Phase 4
- Acute-On-Chronic Liver Failure · Phase 2/Phase 3
- Adjustment Disorders · Phase 2/Phase 3
- Aggression · Phase 2
- Akathisia, Drug-Induced · Phase 2
- Alcohol Drinking · Phase 2
- Alcoholism · Phase 2
- Alzheimer Disease · Phase 1
- Amylases · Phase 1
- Anemia, Sickle Cell · Phase 2
- Anesthesia and Analgesia · Phase 4
- Antipsychotic Agents · Phase 2
- Anxiety · Phase 2
- Anxiety Disorders · Phase 4
- Aphasia, Primary Progressive · Early Phase 1
- Arrhythmias, Cardiac · Phase 3
- Arterial Pressure · Early Phase 1
- Arteriosclerosis · Phase 1/Phase 2
- Ascites · Phase 4
- Asthma · Phase 4
- Autism Spectrum Disorder · Phase 2
- Autonomic Nervous System Diseases · Phase 1
- Back Pain · Phase 2
- Behavior · Phase 2
- Biliary Tract Neoplasms · Phase 2
- Brain Diseases · Phase 2
- Brain Injuries · Phase 4
- Brain Injuries, Traumatic · Phase 4
- Breast Neoplasms · Phase 2
- Burns · Phase 2/Phase 3
- Cachexia · Phase 2
- Cannabis · Phase 1/Phase 2
- Carcinoma, Hepatocellular · Phase 4
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Cardiovascular Diseases · Phase 4
- Central Nervous System Diseases · Phase 2
- Cerebral Hemorrhage · Phase 3
- Cerebrovascular Disorders · Phase 2
- Cholangiocarcinoma · Phase 2
- Chylothorax · Phase 1/Phase 2
- Cigarette Smoking · Phase 4
- Cocaine-Related Disorders · Phase 2
- Colorectal Neoplasms · Phase 3
- Coronary Disease · Phase 3
- COVID-19 · Phase 3
- Craniocerebral Trauma · Phase 2
- Critical Illness · Phase 3
- Death, Sudden, Cardiac · Phase 3
- Dental Anxiety · Phase 2/Phase 3
- Developmental Disabilities · Phase 2
- Diabetes Mellitus, Type 1 · Phase 2
- Diabetes Mellitus, Type 2 · Phase 1
- Diabetic Retinopathy · Phase 1
- Dietary Supplements · Phase 3
- Disease Transmission, Infectious · Phase 2
- DNA Damage · Phase 1
- Dopamine beta-Hydroxylase · Phase 1
- Double Outlet Right Ventricle · Phase 1
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Drug Resistant Epilepsy · Early Phase 1
- Drugs, Generic · Phase 2
- Emotions · Phase 1
- Esophageal and Gastric Varices · Phase 4
- Esophageal Neoplasms · Phase 2
- Essential Tremor · Phase 4
- Fallopian Tube Neoplasms · Phase 1
- Fibromyalgia · Phase 2
- Fibrosis · Phase 4
- Galvanic Skin Response · Phase 1
- Gastritis · Phase 3
- Gastroesophageal Reflux · Phase 4
- Gastrointestinal Neoplasms · Early Phase 1
- General Surgery · Phase 2
- Graves Disease · Phase 4
- Hamartoma · Phase 1
- Headache · Phase 4
- Healthy Volunteers · Phase 2/Phase 3
- Hearing Disorders · Early Phase 1
- Heart Defects, Congenital · Phase 1/Phase 2
- Heart Diseases · Phase 3
- Heart Rate · Phase 1
- Hemangioendothelioma · Phase 4
- Hemangioma · Phase 4
- Hemangioma, Capillary · Phase 2/Phase 3
- Hemangioma, Cavernous, Central Nervous System · Phase 2
- Hemangiosarcoma · Phase 2
- Hemorrhage · Phase 4
- Hemorrhagic Stroke · Phase 3
- Hepatic Encephalopathy · Phase 4
- Hydrocortisone · Phase 4
- Hyperalgesia · Phase 4
- Hypertension, Portal · Phase 4
- Hyperthyroidism · Phase 4
- Hypertrophy, Left Ventricular · Phase 4
- Hypotension · Phase 2
- Hypotension, Orthostatic · Phase 1
- Hypoxia · Early Phase 1
- Ideal Body Weight · Early Phase 1
- Immunologic Factors · Phase 2
- Inflammation · Phase 4
- Intensive Care Units · Phase 3
- Intervertebral Disc Degeneration · Phase 2
- Intestinal Neoplasms · Phase 2
- Intracranial Hemorrhages · Phase 3
- Intracranial Pressure · Phase 3
- Ischemic Stroke · Phase 2
- Kidney Diseases · Phase 2
- Labor, Obstetric · Phase 3
- Liver Cirrhosis · Phase 4
- Liver Cirrhosis, Alcoholic · Phase 4
- Liver Neoplasms · Phase 2
- Low Back Pain · Phase 2
- Lumbar Vertebrae · Phase 2
- Lung Diseases · Phase 2/Phase 3
- Lymphoma · Phase 1
- Macular Degeneration · Phase 2/Phase 3
- Major Depressive Disorder · Phase 1
- Marfan Syndrome · Phase 2
- Melanoma · Phase 2/Phase 3
- Memory · Phase 1
- Menopause · Early Phase 1
- Metabolic Syndrome · Early Phase 1
- Migraine with Aura · Phase 3
- Migraine without Aura · Phase 3
- Molecular Mechanisms of Pharmacological Action · Phase 2
- Mortality · Phase 3
- Movement Disorders · Phase 2
- Multiple Myeloma · Phase 2
- Myocardial Infarction · Phase 3
- Myocardial Ischemia · Phase 3
- Neoplasms · Phase 4
- Nervous System Diseases · Phase 2
- Neuroblastoma · Phase 2
- Obesity · Early Phase 1
- Obsessive-Compulsive Disorder · Phase 4
- Ocular Physiological Phenomena · Phase 2
- Orthostatic Intolerance · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Pain · Phase 2
- Pancreatic Neoplasms · Phase 2
- Panic Disorder · Phase 2
- Peptic Ulcer · Phase 2/Phase 3
- Peritonitis · Phase 4
- Pharmacokinetics · Phase 1
- Pheochromocytoma · Phase 2
- Phobia, Social · Phase 4
- Physiological Effects of Drugs · Phase 2
- Portal Vein · Phase 3
- Postoperative Pain · Phase 2
- Postural Orthostatic Tachycardia Syndrome · Phase 4
- Prediabetic State · Early Phase 1
- Pregnancy, Prolonged · Phase 3
- Primary Dysautonomias · Phase 1/Phase 2
- Procedural Sedation · Phase 3
- Propranolol · Phase 2
- Prostatic Neoplasms · Phase 2
- Psychological Distress · Phase 4
- Pulmonary Disease, Chronic Obstructive · Phase 1
- Regional Blood Flow · Phase 2
- Respiration, Artificial · Phase 3
- Retinopathy of Prematurity · Phase 2/Phase 3
- Sarcoma · Phase 2
- Sarcoma, Kaposi · Phase 2
- Seasonal Affective Disorder · Phase 2
- Self-Injurious Behavior · Phase 2
- Shoulder Pain · Phase 2
- Sleep Apnea, Obstructive · Phase 2
- Smoking Cessation · Phase 3
- Spinal Fusion · Phase 2
- Stomach Neoplasms · Phase 2
- Stress Disorders, Post-Traumatic · Phase 4
- Stress Disorders, Traumatic, Acute · Phase 2
- Stress, Psychological · Phase 4
- Stroke · Phase 3
- Substance-Related Disorders · Phase 2
- Sympathetic Nervous System · Phase 4
- Syncope · Phase 2
- Syncope, Vasovagal · Phase 4
- Tachycardia · Phase 3
- Tachycardia, Supraventricular · Phase 3
- Tardive Dyskinesia · Phase 2/Phase 3
- Telangiectasia, Hereditary Hemorrhagic · Phase 3
- Temporomandibular Joint Disorders · Phase 2
- Tetralogy of Fallot · Phase 1
- Thrombosis · Phase 3
- Tobacco Use Disorder · Phase 4
- Trauma and Stressor Related Disorders · Phase 2/Phase 3
- Trauma, Nervous System · Phase 2
- Tremor · Phase 4
- Troponin · Phase 4
- Tuberous Sclerosis · Phase 2
- Ureteral Neoplasms · Phase 2
- Urethral Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2
- Vasodilation · Early Phase 1
- Ventricular Fibrillation · Phase 3
- Wounds and Injuries · Phase 4
Mechanism of action
- Beta-1 adrenergic receptorANTAGONIST
ADRB1 antagonist
- Beta-2 adrenergic receptorANTAGONIST
ADRB2 antagonist
Combination products
inderide
with hydrochlorothiazide
Also known as inderide la, propranolol hydrochloride & hydrochlorothiazide
Approval history
- approvedPriority reviewNov 13, 1967
Chemistry & pharmacology
SMILES
CC(C)NCC(O)COc1cccc2ccccc12- Mol. weight
- 259.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL27 ↗
- WikipediaPropranolol ↗
- NCATS9Y8NXQ24VQ ↗
- ChEMBLCHEMBL1671 ↗
Also known as
- 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
- 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
- 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
- 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
- angilol
- angilol
- apsolol
- apsolol
- av-83
- avlocardyl
- avlocardyl
- ay-64043
- ay-64043
- bedranol
- bedranol
- bedranol s.r.
- berkolol
- berkolol
- betadur cr
- betalong
- beta-prograne mr
- beta-propranolol
- beta-propranolol
- beta-propranolol
- cardinol
- cardinol
- dl-propranolol
- dupromex
- half-beprane cr
- half-betadur cr
- half beta-prograne mr
- half-inderal la
- half propanix la
- half propatard la
- hemangiol
- ici-45520
- ici-45520
- inderal
- inderal
- inderal
- inderal
- inderal la
- inderal la
- inderide-40/25
- inderide-40/25
- inderide-80/25
- inderide-80/25
- innopran
- innopran
- innopran xl
- innopran xl
- innopran xl
- lederpronol
- lopranol la
- probeta la
- propanalol
- propanalol
- propanix-10
- propanix-160
- propanix-160 sr
- propanix-40
- propanix-80
- propanix la
- propanolol
- propanolol
- propanolol
- propatard la
- propranolol
- propranolol
- propranolol
- propranolol
- propranolol
- propranolol
- propranolol
- propranolol
- propranolol
- propranolol
- propranolol cr
- propranolol hcl
- propranolol hcl
- propranolol hcl
- propranolol hydrochloride
- propranolol hydrochloride
- propranolol hydrochloride
- propranolol hydrochloride
- propranolol hydrochloride
- propranolol hydrochloride intensol
- propranolol hydrochloride intensol
- propranololo
- propranololo
- propranololum
- propranololum
- racemic propranolol
- rapranol sr
- sagittol
- sagittol
- slo-blok
- slo-pro
- sloprolol
- sloprolol
- syprol
- tesnol
- tesnol
- β-propranolol
- β-propranolol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07271485 | Early Phase 1 (Phase 1) | Dec 19, 2025 | Bloom Mental Health, LLC |
| NCT07311915 | N/A | Dec 1, 2025 | Southeast University |
| NCT07091279 | Phase 2 | Nov 22, 2025 | Columbia University, Department of Defense, State of New York |
| NCT06870370 | Phase 3 | Sep 20, 2025 | Tanta University |
| NCT07067853 | N/A | Sep 1, 2025 | University of Indonesia |
| NCT07147972 | Phase 3 | Aug 20, 2025 | Fayoum University |
| NCT06972056 | Phase 4 | Jul 9, 2025 | AbbVie, Mayo Clinic, Patient-Centered Outcomes Research Institute, University of Iowa |
| NCT06960850 | N/A | Jun 1, 2025 | Federal Teaching Hospital Abakaliki |
| NCT06982183 | Phase 4 | May 27, 2025 | United States Army |
| NCT06839144 | Phase 2 | Mar 12, 2025 | National Cancer Institute (NCI), Tel Aviv University |
| NCT06833320 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2025 | Columbia University, Department of Defense |
| NCT06836856 | Phase 1/Phase 2 (Phase 2) | Feb 28, 2025 | Mansoura University |
| NCT06787066 | Early Phase 1 (Phase 1) | Feb 28, 2025 | University of Missouri |
| NCT06798363 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2025 | Sichuan University |
| NCT06719804 | Early Phase 1 (Phase 1) | Dec 5, 2024 | Capital Medical University, Peking University |
| NCT06775080 | Phase 2 | Dec 1, 2024 | Fudan University |
| NCT06670976 | Phase 1 | Nov 15, 2024 | State University of New York, Buffalo |
| NCT06499116 | Phase 4 | Oct 31, 2024 | Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina, Institut Català de la Salut, University of Barcelona |
| NCT06445166 | Phase 2 | Oct 31, 2024 | Washington University in St. Louis |
| NCT06422494 | N/A | Sep 30, 2024 | Radboud University |
Organizations
Research & Development (270)
Marketing (67)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ANDA Repository | For profit | MKTG | Oct 22, 1985 |
| Actavis | For profit | MKTG | May 15, 1986 |
| Adare Pharmaceuticals | For profit | MKTG | Jul 15, 2011 |
| AiPing Pharm Inc | For profit | MKTG | Oct 22, 1986 |
| Akrimax Pharmaceuticals | For profit | NDA2 | Sep 4, 1973 |
| Allied Pharmaceutical Services | For profit | MKTG | Feb 26, 2003 |
| American Home Products | For profit | NDA2 | Jul 3, 1985 |
| American Home Products | For profit | NDA | — |
| American Home Products | For profit | MKTG | Jun 15, 1979 |
| Amici | For profit | MKTG | Aug 4, 1986 |
| Amta | For profit | MKTG | Jan 6, 2020 |
| Ani Pharmaceuticals | For profit | NDA2 | Apr 19, 1983 |
| Ani Pharmaceuticals | For profit | MKTG | Apr 19, 1983 |
| Athenex, Inc. | For profit | MKTG | Aug 29, 2000 |
| Baxalta | For profit | NDA2 | Nov 13, 1967 |
| Boehringer Ingelheim | For profit | MKTG | Jul 7, 1986 |
| Chartwell Pharmaceuticals | For profit | MKTG | Aug 29, 2000 |
| Chartwell Pharmaceuticals | For profit | SYN | Jun 13, 1986 |
| DAVA Pharmaceuticals | For profit | MKTG | Jul 30, 1985 |
| Duramed Research | For profit | MKTG | Sep 9, 1985 |
| EXTROVIS | For profit | MKTG | Feb 15, 2007 |
| Endo Pharmaceuticals | For profit | MKTG | Apr 14, 1986 |
| Eton Pharmaceuticals, Inc. | For profit | MKTG | Mar 14, 2014 |
| Fosun | For profit | MKTG | Feb 26, 2003 |
| Fosun | For profit | SYN | Jun 13, 1986 |
| Fresenius | For profit | MKTG | Aug 31, 2001 |
| Hikma | For profit | MKTG | Jan 31, 2008 |
| Hikma | For profit | SYN | May 15, 1987 |
| Hikma | For profit | SYN | May 15, 1987 |
| IPCA Laboratories Ltd. | For profit | MKTG | Jun 2, 2008 |
| Impax Laboratories | For profit | MKTG | Apr 6, 1988 |
| Innogenix | For profit | MKTG | Oct 22, 1985 |
| Interpharm | For profit | MKTG | May 5, 1987 |
| Inwood Laboratories | For profit | MKTG | Apr 11, 1989 |
| Lederle | For profit | MKTG | — |
| Lupin | For profit | MKTG | Jan 12, 2024 |
| Lupin | For profit | SYN | Jan 12, 2024 |
| Mankind Pharma | For profit | MKTG | Jan 27, 2026 |
| Mylan | For profit | MKTG | Nov 19, 1985 |
| Nortec Dev Assoc | For profit | MKTG | Jan 26, 2007 |
| Northstar Healthcare | Academic/Hospital | MKTG | Jan 10, 2008 |
| PH HEALTH | For profit | MKTG | Apr 14, 1986 |
| Par Pharmaceuticals | For profit | MKTG | Oct 22, 1986 |
| Pharmaceutical Associates | For profit | MKTG | — |
| Pierre Fabre | For profit | NDA2 | Mar 14, 2014 |
| Pierre Fabre | For profit | MKTG | Mar 14, 2014 |
| Puracap Pharmaceutical | For profit | MKTG | — |
| R.P. Scherer | For profit | MKTG | Jul 15, 2011 |
| Rising Pharmaceuticals | For profit | MKTG | Apr 1, 1987 |
| Roxane Laboratories | For profit | MKTG | May 15, 1987 |
| SOLOPAK | For profit | MKTG | — |
| Sandoz | For profit | MKTG | — |
| Schering | For profit | MKTG | Aug 6, 1985 |
| Schering-Plough | For profit | MKTG | Aug 6, 1985 |
| Smith & Nephew | For profit | MKTG | — |
| Strides Pharma Science | For profit | MKTG | Oct 22, 1986 |
| Superpharm | For profit | MKTG | Jun 8, 1988 |
| Teva | For profit | SYN | Jun 23, 1986 |
| Teva | For profit | MKTG | Apr 11, 1986 |
| Upsher-Smith Laboratories | For profit | MKTG | Mar 6, 2009 |
| Vintage | For profit | MKTG | Apr 14, 1986 |
| Warner Chilcott | For profit | MKTG | Jan 26, 1988 |
| Watson Pharmaceuticals | For profit | MKTG | Apr 18, 1986 |
| West-Ward Pharmaceutical | For profit | MKTG | May 15, 1987 |
| Wyeth | For profit | NDA2 | Nov 13, 1967 |
| Wyeth | For profit | SYN | Jun 15, 1979 |
| Zydus Discovery DMCC | For profit | MKTG | Mar 25, 2011 |